title: Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
abstract: Mucopolysaccharidoses (MPS) are inherited metabolic diseases caused by mutations in genes coding for lysosomal enzymes involved in the degradation of glycosaminoglycans (GAGs). Dysfunction of any of these enzymes results in the accumulation of GAGs, which leads to severe clinical symptoms and significantly shortened life span. Several kinds of therapies have been proposed to treat MPS, including bone marrow or stem cell transplantation, enzyme replacement therapy, and gene therapy. Another option is substrate reduction therapy (SRT), in which synthesis of GAGs is inhibited. Recent studies employing in vitro and animal models suggested that this therapy may be efficient in decreasing levels of GAGs in MPS cells, including those bearing two null alleles of the affected gene. Results of behavioral tests in animals as well as some preliminary clinical observations with pediatric patients corroborated the suggestions about possible efficacy of SRT in MPS treatment, including brain functions. Efficient reduction of GAG levels in MPS cells homozygous for null mutations may be intriguing in the commonly accepted scheme of SRT mode of action. In this paper, we propose an explanation of this phenomenon, based on already known facts. Thus, we suggest that SRT may lead to reduction of GAG levels in MPS cells due to inhibition of efficiency of GAG synthesis combined with (a) any readthrough of the stop codon, (b) dilution of already accumulated GAGs due to cell growth followed by cell divisions, and (c) action of endoglycosidases degrading GAGs, e.g., heparanase, in combination with functional GAG-specific hydrolases.
authors.affiliation: Department of Neurology, Medical University of Gdańsk, Dębinki 7, 80-211, Gdańsk, Poland. zytabm@gumed.edu.pl
authors.forename: Zyta
authors.initials: Z
authors.lastname: Banecka-Majkutewicz
authors.forename: Joanna
authors.initials: J
authors.lastname: Jakóbkiewicz-Banecka
authors.forename: Magdalena
authors.initials: M
authors.lastname: Gabig-Cimińska
authors.forename: Alicja
authors.initials: A
authors.lastname: Węgrzyn
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Węgrzyn
mesh_terms: D000818:Animals; D015316:Genetic Therapy; D019833:Genistein / Q000627:therapeutic use*; D006025:Glycosaminoglycans / Q000096:biosynthesis / Q000378:metabolism*; D006801:Humans; D008247:Lysosomes / Q000187:drug effects* / Q000201:enzymology; D058990:Molecular Targeted Therapy; D009083:Mucopolysaccharidoses / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D006025:Glycosaminoglycans; D019833:Genistein